ATE306903T1 - Verminderung von adhäsionen durch gesteuerte verabreichung von aktivsauerstoffinhibitoren - Google Patents

Verminderung von adhäsionen durch gesteuerte verabreichung von aktivsauerstoffinhibitoren

Info

Publication number
ATE306903T1
ATE306903T1 AT96908878T AT96908878T ATE306903T1 AT E306903 T1 ATE306903 T1 AT E306903T1 AT 96908878 T AT96908878 T AT 96908878T AT 96908878 T AT96908878 T AT 96908878T AT E306903 T1 ATE306903 T1 AT E306903T1
Authority
AT
Austria
Prior art keywords
adhesions
active oxygen
reduction
oxygen inhibitors
sod
Prior art date
Application number
AT96908878T
Other languages
English (en)
Inventor
Keith Baker
Arthur J Coury
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of ATE306903T1 publication Critical patent/ATE306903T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Catalysts (AREA)
AT96908878T 1995-03-24 1996-03-20 Verminderung von adhäsionen durch gesteuerte verabreichung von aktivsauerstoffinhibitoren ATE306903T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41021995A 1995-03-24 1995-03-24
PCT/US1996/003813 WO1996029987A1 (en) 1995-03-24 1996-03-20 Reduction of adhesions using controlled delivery of active oxygen inhibitors

Publications (1)

Publication Number Publication Date
ATE306903T1 true ATE306903T1 (de) 2005-11-15

Family

ID=23623783

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96908878T ATE306903T1 (de) 1995-03-24 1996-03-20 Verminderung von adhäsionen durch gesteuerte verabreichung von aktivsauerstoffinhibitoren

Country Status (8)

Country Link
US (2) US5785993A (de)
EP (1) EP0814774B1 (de)
JP (1) JP3145409B2 (de)
AT (1) ATE306903T1 (de)
AU (1) AU704222B2 (de)
CA (1) CA2215317C (de)
DE (1) DE69635301T2 (de)
WO (1) WO1996029987A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE306903T1 (de) * 1995-03-24 2005-11-15 Genzyme Corp Verminderung von adhäsionen durch gesteuerte verabreichung von aktivsauerstoffinhibitoren
US6039757A (en) * 1997-03-12 2000-03-21 Cardiosynopsis, Inc. In situ formed fenestrated stent
CA2283708A1 (en) * 1997-03-20 1998-09-24 Focal, Inc. Biodegradable tissue retractor
EP0887076A3 (de) * 1997-05-07 1999-03-31 Saturnus A.G. Verhinderung von Gewebeverklebung und ein dafür vorgesehenes endoskopisches System zum Aufblasen einer Körperhöhle
AU1520699A (en) 1997-11-07 1999-05-31 Johns Hopkins University, The Methods for treatment of disorders of cardiac contractility
US6627663B2 (en) 1998-08-03 2003-09-30 W. Jerry Easterling Noninvasive method for treating hemangiomas through transdermal delivery of calcium channel blocker agents and medicament for use in such method
US6031005A (en) * 1998-08-03 2000-02-29 Easterling; W. Jerry Composition and method for treating Peyronie's disease and related connective tissue disorders
US6197309B1 (en) * 1998-08-03 2001-03-06 Ronald E. Wheeler Prostate formula
US6525100B1 (en) 1998-08-03 2003-02-25 W. Jerry Easterling Composition and method for treating peyronie's disease and related fibrotic tissue disorders
US20080114092A1 (en) * 1998-12-04 2008-05-15 Incept Llc Adhesion barriers applicable by minimally invasive surgery and methods of use thereof
EA006402B1 (ru) 1999-12-23 2005-12-29 Пфайзер Продактс Инк. Комбинация лекарства и целлюлозного полимера, повышающего концентрацию; способ введения лекарства и водный раствор (варианты)
JP2003528148A (ja) * 2000-03-28 2003-09-24 デロレンゾ、ロバート・ジェイ 損傷に際して神経細胞中に形成される新規カルシウム損傷電流の阻害は神経細胞死を抑制する
FI20010898A0 (fi) * 2001-04-30 2001-04-30 Ylae Herttuala Seppo Ekstrasellulaarinen superoksididismutaasi (EC-SOD) geeniterapia restenoosoin ehkäisemiseksi
AU2003224587A1 (en) * 2002-04-30 2003-11-17 Fit Biotech Oyj Plc Medical device
CN100490900C (zh) * 2002-08-20 2009-05-27 精密技术公司 骨生长诱导材料的携带和输送用组合物以及生产和应用该组合物的方法
AU2003279823A1 (en) 2002-10-28 2004-05-25 Northgate Technologies Inc. Dual-capacity insufflator tube
US7654975B2 (en) 2003-04-24 2010-02-02 Northgate Technologies, Inc. Mixed-gas insufflation system
CA2824210A1 (en) * 2003-09-23 2005-04-21 Orthocon, Inc. Absorbable implants and methods for their use in hemostasis and for the treatment of osseous defects
US7955616B2 (en) * 2003-09-23 2011-06-07 Orthocon, Inc. Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
DE202004021703U1 (de) 2003-10-07 2010-05-27 Northgate Technologies Inc., Elgin Vorrichtung zur Abgabe einer Substanz in eine Körperhöhle
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
US7332179B2 (en) * 2003-12-12 2008-02-19 Kimberly-Clark Worldwide, Inc. Tissue products comprising a cleansing composition
US20050244480A1 (en) * 2004-04-30 2005-11-03 Kimberly-Clark Worldwide, Inc. Pre-wipes for improving anal cleansing
US7642395B2 (en) * 2004-12-28 2010-01-05 Kimberly-Clark Worldwide, Inc. Composition and wipe for reducing viscosity of viscoelastic bodily fluids
US20060140899A1 (en) * 2004-12-28 2006-06-29 Kimberly-Clark Worldwide, Inc. Skin cleansing system comprising an anti-adherent formulation and a cationic compound
US8414907B2 (en) 2005-04-28 2013-04-09 Warsaw Orthopedic, Inc. Coatings on medical implants to guide soft tissue healing
US9119901B2 (en) 2005-04-28 2015-09-01 Warsaw Orthopedic, Inc. Surface treatments for promoting selective tissue attachment to medical impants
EP1906992A1 (de) * 2005-06-28 2008-04-09 Life Science Investments Limited Verwendung eines gemisches von superoxid-dismutase und catalase zur behandlung von entzündlichen hauterkrankungen
CA2629897A1 (en) * 2005-11-14 2007-05-24 Ud Technology Corporation Novel hydrogels and uses thereof
US7706852B2 (en) 2006-01-30 2010-04-27 Nellcor Puritan Bennett Llc System and method for detection of unstable oxygen saturation
ES2666919T3 (es) 2006-08-04 2018-05-08 Northgate Technologies, Inc. Puerto permanente para acceso a un cuerpo
US20080241270A1 (en) * 2007-03-30 2008-10-02 Neal Robert A Fluid composition for inhibiting surgical adhesion formation and related method of production
CA2780274C (en) 2009-11-09 2018-06-26 Spotlight Technology Partners Llc Fragmented hydrogels
US9700650B2 (en) 2009-11-09 2017-07-11 Spotlight Technology Partners Llc Polysaccharide based hydrogels
EP2922919B1 (de) 2012-11-21 2020-03-25 University Of Louisville Research Foundation, Inc. Zusammensetzungen und verfahren zur reduzierung von oxidativen schäden
US9572595B1 (en) 2014-03-05 2017-02-21 Northgate Technologies Inc. In-dwelling port for access into a body
EP3256136A4 (de) 2015-02-09 2018-11-21 University Of Louisville Research Foundation, Inc. Ophthalmische zusammensetzungen und verfahren zur reduzierung von oxidativen schäden einer augenlinse
US10590257B2 (en) 2016-09-26 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Biomimetic, moldable, self-assembled cellulose silica-based trimeric hydrogels and their use as viscosity modifying carriers in industrial applications
CN106468668B (zh) * 2016-09-28 2019-03-12 北京凯视佳光电设备有限公司 工业相机圆柱检测方法
US11969526B2 (en) 2017-04-03 2024-04-30 The Board Of Trustees Of The Leland Stanford Junior University Adhesion prevention with shear-thinning polymeric hydrogels
US11975123B2 (en) 2018-04-02 2024-05-07 The Board Of Trustees Of The Leland Stanford Junior University Adhesion prevention with shear-thinning polymeric hydrogels
EP3746393A4 (de) 2018-02-02 2021-11-03 Galen Therapeutics Llc Vorrichtung und verfahren zum schutz von neuronen und zur verminderung von entzündungen und narbenbildung
WO2020072495A1 (en) 2018-10-01 2020-04-09 The Board Of Trustees Of The Leland Stanford Junior University Injectable hydrogels for controlled release of immunomodulatory compounds

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784585A (en) * 1971-10-21 1974-01-08 American Cyanamid Co Water-degradable resins containing recurring,contiguous,polymerized glycolide units and process for preparing same
US4371519A (en) * 1972-06-05 1983-02-01 Hettinger Jr William P Methods of treating cellular tissue
US4897308A (en) * 1975-06-30 1990-01-30 L'oreal Compositions comprising aqueous dispersions of lipid spheres
US4563349A (en) * 1980-07-30 1986-01-07 Takeda Chemical Industries, Ltd. Superoxide dismutase, its immobilized form, and their production and use
ATE37983T1 (de) * 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US5286763A (en) * 1983-03-22 1994-02-15 Massachusetts Institute Of Technology Bioerodible polymers for drug delivery in bone
JPS6014861A (ja) * 1983-07-05 1985-01-25 株式会社日本メデイカル・サプライ 癒着防止材
DE3485284D1 (de) * 1983-10-03 1992-01-02 Chiron Corp Klonieren von superoxid-dismutase und expression in mikroorganismen.
US4511478A (en) * 1983-11-10 1985-04-16 Genetic Systems Corporation Polymerizable compounds and methods for preparing synthetic polymers that integrally contain polypeptides
US4873292A (en) * 1984-12-28 1989-10-10 Research Development Corporation Of Japan Antithrombogenic synthetic polymer and process for its preparation
US4760051A (en) * 1985-01-24 1988-07-26 Pickart Loren R Use of GHL-Cu as a wound-healing and anti-inflammatory agent
CS254355B1 (en) * 1985-04-10 1988-01-15 Vladimir Saudek Soluble and biodegradatable copolymeres activated for bond of biologicaly active substances
JPH084504B2 (ja) * 1985-04-26 1996-01-24 味の素株式会社 安定化ス−パ−オキサイドジスムタ−ゼ
IN166447B (de) * 1985-11-27 1990-05-12 Ethicon Inc
US4889722A (en) * 1985-12-16 1989-12-26 Ethicon, Inc. Method for inhibiting post-surgical adhesion formation by the topical administration of tissue plasminogen activator
US4806621A (en) * 1986-01-21 1989-02-21 Massachusetts Institute Of Technology Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
US4976959A (en) * 1986-05-12 1990-12-11 Burroughs Wellcome Co. T-PA and SOD in limiting tissue damage
US4741872A (en) * 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules
US5160745A (en) * 1986-05-16 1992-11-03 The University Of Kentucky Research Foundation Biodegradable microspheres as a carrier for macromolecules
IT1198449B (it) * 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
US5547988B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Alleviating signs of dermatological aging with glycolic acid lactic acid or citric acid
US5260204A (en) * 1987-03-14 1993-11-09 Boehringer Ingelheim International Gmbh Human manganese superoxide dismutase (hMn-SOD)
US5227405A (en) * 1987-03-31 1993-07-13 Duke University Superoxide dismutase mimic
US5223538A (en) * 1987-03-31 1993-06-29 Duke University Superoxide dismutase mimic
DE3853493T2 (de) * 1987-05-28 1995-07-27 Kuraray Co Superoxid-Dismutase-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel.
IL82834A (en) * 1987-06-09 1990-11-05 Yissum Res Dev Co Biodegradable polymeric materials based on polyether glycols,processes for the preparation thereof and surgical artiicles made therefrom
HU209955B (en) * 1987-07-01 1994-12-28 Genentech Inc Process for producing pharmaceutical compositions containing tissue- -plasminogen-activator of poor solubility for inhibiting production and regeneration of deformities
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4804691A (en) * 1987-08-28 1989-02-14 Richards Medical Company Method for making a biodegradable adhesive for soft living tissue
US5364622A (en) * 1987-12-04 1994-11-15 Dr. Karl Thomae Gmbh Methods for preventing adhesions to organs and parts of organs by application of tissue plasminogen activator and hydroxyethylcellulose hydrogel
US4888413A (en) * 1988-01-11 1989-12-19 Domb Abraham J Poly(propylene glycol fumarate) compositions for biomedical applications
US4898734A (en) * 1988-02-29 1990-02-06 Massachusetts Institute Of Technology Polymer composite for controlled release or membrane formation
US5057494A (en) * 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
US5213580A (en) * 1988-08-24 1993-05-25 Endoluminal Therapeutics, Inc. Biodegradable polymeric endoluminal sealing process
US5328471A (en) * 1990-02-26 1994-07-12 Endoluminal Therapeutics, Inc. Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5126141A (en) * 1988-11-16 1992-06-30 Mediventures Incorporated Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides
US4911926A (en) * 1988-11-16 1990-03-27 Mediventures Inc. Method and composition for reducing postsurgical adhesions
US5135751A (en) * 1988-11-16 1992-08-04 Mediventures Incorporated Composition for reducing postsurgical adhesions
CA2004740A1 (en) * 1988-12-07 1990-06-07 Cary Linsky Low molecular weight heparin, heparinoid and hexuronyl hexosaminoglycan sulfate containing adhesion prevention barrier and process
US5108755A (en) * 1989-04-27 1992-04-28 Sri International Biodegradable composites for internal medical use
IL90193A (en) * 1989-05-04 1993-02-21 Biomedical Polymers Int Polurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same
US4994277A (en) * 1989-10-31 1991-02-19 Pfizer Hospital Products Group, Inc. Use of xanthan gum for preventing adhesions
US5175235A (en) * 1990-06-04 1992-12-29 Nova Pharmaceutical Corporation Branched polyanhydrides
EP0589871B1 (de) * 1990-02-13 2000-04-26 Ethicon, Inc. Peritoneal wirksame medikamente
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US5219564A (en) * 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
US5143731A (en) * 1990-08-07 1992-09-01 Mediventures Incorporated Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5217966A (en) * 1990-09-13 1993-06-08 The Regents Of The University Of California Synthetic drug molecules that mimic metalloenzymes
US5410016A (en) * 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5529914A (en) * 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
US5288502A (en) * 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
JP3011768B2 (ja) * 1992-02-28 2000-02-21 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 組織接触材料および制御放出キャリアとしての光重合性生分解性親水ゲル
US5384333A (en) * 1992-03-17 1995-01-24 University Of Miami Biodegradable injectable drug delivery polymer
AU3972893A (en) * 1992-04-03 1993-11-08 Baylor College Of Medicine Gene therapy using the intestine
US5698189A (en) * 1993-03-23 1997-12-16 Focal, Inc. Method for local application of polymeric material to tissue
US5849035A (en) * 1993-04-28 1998-12-15 Focal, Inc. Methods for intraluminal photothermoforming
US5519035A (en) * 1993-07-02 1996-05-21 Cornell Research Foundation, Inc. Treatment of stroke or in anticipation of the occurrence of brain ischemia
DE69430243T2 (de) * 1993-12-01 2002-10-17 Bioartificial Gel Technologies Inc., Montreal Hydrogel auf basis von albumin
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
JP3492787B2 (ja) * 1994-04-15 2004-02-03 信越化学工業株式会社 固形製剤のコーティング用水性エマルジョンの濃縮方法
IL109539A0 (en) * 1994-05-03 1994-08-26 Yissum Res Dev Co Substained-release pharmaceutical system for the delivery of antioxidants
US5478837A (en) 1994-06-07 1995-12-26 University Of Southern California Use of quinacrine in preventing adhesion formation
US5562594A (en) * 1994-06-10 1996-10-08 Duke University Shielded mini-applicator system for radioactive source treatment of cancer of the uterine cervix
ATE306903T1 (de) * 1995-03-24 2005-11-15 Genzyme Corp Verminderung von adhäsionen durch gesteuerte verabreichung von aktivsauerstoffinhibitoren
US5527864A (en) * 1995-08-08 1996-06-18 Suggs; Laura J. Poly(propylene fumarate-co-ethylene oxide)

Also Published As

Publication number Publication date
JPH10508872A (ja) 1998-09-02
DE69635301T2 (de) 2006-07-20
WO1996029987A1 (en) 1996-10-03
EP0814774A1 (de) 1998-01-07
AU5257596A (en) 1996-10-16
CA2215317C (en) 2002-07-23
US6780427B2 (en) 2004-08-24
JP3145409B2 (ja) 2001-03-12
AU704222B2 (en) 1999-04-15
DE69635301D1 (de) 2006-03-02
CA2215317A1 (en) 1996-10-03
US20010046503A1 (en) 2001-11-29
US5785993A (en) 1998-07-28
EP0814774B1 (de) 2005-10-19

Similar Documents

Publication Publication Date Title
ATE306903T1 (de) Verminderung von adhäsionen durch gesteuerte verabreichung von aktivsauerstoffinhibitoren
ATE238813T1 (de) Wirkstoffformulierungen mit verzögerter freisetzung
ES2171186T3 (es) Composiciones liquidas de difusion.
TR199901411T2 (xx) Analjezik etkili yeni bile�imler.
ATE195250T1 (de) Lokale verabreichung von fibrinolyse verstärkendemitteln
NO20074292L (no) Anvendelse av buprenorfin i polymermatriks og leveringssystemer
GB9212511D0 (en) Pharmaceutical compositions
PT1028707E (pt) Formulacoes oftalmicas de libertacao controlada contendo medicamentos soluveis em agua
DE60023138D1 (de) Verwendung eines biologisch abbaubaren Polymers
PT1006935E (pt) Sistema de entrega controlada liquido de alta viscosidade
DE69938552D1 (de) Spritzgiessbare feste verabreichungsysteme
IS4675A (is) Örþeytur til að nota sem burðarefni við inngjöf virkra efna
DK0689426T3 (da) Terapeutisk middel til behandling af melanomer
TR199700943T1 (xx) Organik bile�iklerde veya bu bile�iklere ili�kin geli�meler.
DE69129696D1 (de) Polymeres arzneimittelabgabesystem
EP0598337A3 (de) Arznei Zusammensetzungen, die ein Arzneimittel, ein quervernetztes Polymer, ein Öl, und ein grenzflächenaktives Mittel enthalten.
DE50004443D1 (de) Wirkstoffhaltige komposition sowie deren herstellung und verwendung
DE69619052D1 (de) Feste, wasserfreie, pharmazeutische Zubereitungen für vaginale Verwendung
TR199701520T1 (xx) Ac�n�n iyile�tirilmesi i�in analjesik bile�ikleri �reten h�cre soyu.
CA2278814A1 (en) Electro-release systems, modified electrodes and their use
BR9810285A (pt) Solução, composição farmacêutica, e, cápsula de gelatina.
DE59703910D1 (de) Verwendung von asparaginsäure-haltigen polymeren in mit bioziden versetzten kühlkreisläufen
ES2165970T3 (es) Forma farmaceutica solida con principio activo distribuido en un material polimerico.
ATE235909T1 (de) Biologisch kompatible und biologisch abbaubare zubereitungen enthaltend hyaluronsäure und deren derivate zur behandlung von geschwüren im verdauungsapparat
AU3819297A (en) Protein-containing polymer composition for oral administration

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties